Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Warns Decode Genetics of Potential Delisting

NEW YORK (GenomeWeb News) – Decode Genetics has received a letter from Nasdaq informing the firm that it currently does not comply with regulations regarding the market value of its stock.

The letter stated that for 10 consecutive trading days the market value of Decode's common stock has been below $50 million, the minimum level required for continued listing on the Nasdaq Global Market. The firm’s shares also do not comply with an alternative test set forth by a Nasdaq rule, which requires total assets and total revenue of $50 million each for the most recently completed fiscal year or two of the last three most recently completed fiscal years.   

If Decode does not regain compliance by Oct. 30, Nasdaq said that its shares would be delisted. If the company fails to meet the requirements for continued listing on the Nasdaq Global Market, it will consider whether to apply to transfer its common stock to the Nasdaq Capital Market.

Decode’s shares closed Friday at $.33.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.